News
ENLV
4.460
+0.45%
0.020
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
By Rachael Green, Benzinga
News Direct · 2d ago
Israeli Ministry Of Health Clears Way For Human Trials Of Allocetra
Benzinga · 3d ago
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
By Rachael Green, Benzinga
News Direct · 3d ago
Enlivex Therapeutics Granted U.S. Patent #11512289: Combination immune therapy and cytokine control therapy for cancer treatment
Benzinga · 5d ago
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with a PD1 checkpoint inhibitor in a murine model of o...
GlobeNewswire · 6d ago
Enlivex Says FDA Approves Investigational New Drug Application for Allocetra Trial to Treat Solid Tumors; Shares Rise
Enlivex Says FDA Approves Investigational New Drug Application for Allocetra Trial to Treat Solid Tumors; Shares Rise
MT Newswires · 6d ago
Enlivex Announces Dosing Of The First Patient In Phase I/II Trial Evaluating Allocetra Alone And In Combination With A PD1 Checkpoint Inhibitor In Patients With Advanced Solid Tumors
Benzinga · 11/15 13:03
Enlivex Therapeutics Granted U.S. Patent #11497767 Combination immune therapy and cytokine control therapy for cancer treatment
Benzinga · 11/15 11:29
Enlivex Doses First Patient in Phase 1/2 Trial of Allocetra to Treat Solid Tumors
Enlivex Doses First Patient in Phase 1/2 Trial of Allocetra to Treat Solid Tumors
MT Newswires · 11/15 11:14
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 11/11 14:05
BRIEF-Arix Bioscience Says Portfolio Co Imara Announces Merger Deal With Enliven Therapeutics
Reuters · 10/14 06:18
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the ...
GlobeNewswire · 10/03 12:13
Enlivex to Present at Upcoming Investor and Media Conferences
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following inve...
GlobeNewswire · 09/13 12:00
BRIEF-Enlivex Announces New Preclinical Data In Murine Mesothelioma Model
BRIEF-Enlivex Announces New Preclinical Data In Murine Mesothelioma Model
Reuters · 09/12 13:40
Enlivex Highlights Presentation Of Preclinical Data In Murine Mesothelioma Model At ESMO Congress 2022
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a substantial and
Benzinga · 09/12 12:15
Enlivex to gets US patent covering use of cell therapy Allocetra
Enlivex Therapeutics (NASDAQ:ENLV) <a href="https://see...
Seekingalpha · 09/06 17:41
Enlivex Therapeutics Gets Notice of Allowance for US Patent Application for Allocetra; Shares Rise
Enlivex Therapeutics Gets Notice of Allowance for US Patent Application for Allocetra; Shares Rise
MT Newswires · 09/06 09:54
Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Enlivex Therapeutics (NASDAQ:ENLV) <a href="https://seekingalp...
Seekingalpha · 08/29 12:52
Enlivex Receives Notice Of Allowance For Japanese Patent Application Covering Allocetra Derived From Pooled Donor Cells
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the &amp;ldquo, Company&amp;rdquo, )), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today
Benzinga · 08/29 12:10
Enlivex Therapeutics Receives Notice of Allowance for Allocetra Patent Application in Japan
Enlivex Therapeutics Receives Notice of Allowance for Allocetra Patent Application in Japan
MT Newswires · 08/29 09:44
More
Webull provides a variety of real-time ENLV stock news. You can receive the latest news about Enlivex Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.